- Home
- GILD vs NEE Comparison
GILD vs NEE Comparison
Compare GILD & NEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- NEE
- Stock Information
- Founded
- GILD 1987
- NEE 1925
- Country
- GILD United States
- NEE United States
- Employees
- GILD N/A
- NEE N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- NEE Electric Utilities: Central
- Sector
- GILD Health Care
- NEE Utilities
- Exchange
- GILD Nasdaq
- NEE Nasdaq
- Market Cap
- GILD 138.7B
- NEE 153.9B
- IPO Year
- GILD 1992
- NEE N/A
- Fundamental
- Price
- GILD $110.17
- NEE $77.49
- Analyst Decision
- GILD Buy
- NEE Buy
- Analyst Count
- GILD 24
- NEE 10
- Target Price
- GILD $110.95
- NEE $88.00
- AVG Volume (30 Days)
- GILD 6.3M
- NEE 11.2M
- Earning Date
- GILD 08-07-2025
- NEE 07-23-2025
- Dividend Yield
- GILD 2.87%
- NEE 2.92%
- EPS Growth
- GILD 1118.07
- NEE N/A
- EPS
- GILD 4.73
- NEE 2.67
- Revenue
- GILD $28,735,000,000.00
- NEE $25,269,000,000.00
- Revenue This Year
- GILD $1.69
- NEE $15.53
- Revenue Next Year
- GILD $3.67
- NEE $9.42
- P/E Ratio
- GILD $23.29
- NEE $29.02
- Revenue Growth
- GILD 4.68
- NEE N/A
- 52 Week Low
- GILD $70.78
- NEE $61.72
- 52 Week High
- GILD $119.96
- NEE $86.10
- Technical
- Relative Strength Index (RSI)
- GILD 51.17
- NEE 67.37
- Support Level
- GILD $107.75
- NEE $71.26
- Resistance Level
- GILD $110.90
- NEE $75.83
- Average True Range (ATR)
- GILD 2.31
- NEE 1.44
- MACD
- GILD -0.38
- NEE 0.29
- Stochastic Oscillator
- GILD 33.99
- NEE 98.34
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About NEE NextEra Energy Inc.
NextEra Energy's regulated utility, Florida Power & Light, is the largest rate-regulated utility in Florida. The utility distributes power to over 6 million customer accounts in Florida and owns 36 gigawatts of generation. FP&L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with more than 37 GW of generation capacity, including natural gas, nuclear, wind, and solar.